We have previously shown that adoptive transfer of a low dose of Tlr9-/–FRC (200000 FRC/mouse) improved the therapeutic efficacy in CLP-induced sepsis compared with the treatment with the same amount of WT-FRC (4, 6). The gene discussed is TLR9; the disease is Sepsis.